Efficacy and Safety of Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids in Gastric Cancer Malignant Ascites: a Phase I/II Clinical Study (IPIZA)
Latest Information Update: 09 Jan 2025
Price :
$35 *
At a glance
- Drugs Sintilimab (Primary) ; Zoledronic acid (Primary)
- Indications Adenocarcinoma; Gastric cancer; Malignant ascites
- Focus Adverse reactions; Therapeutic Use
- Acronyms IPIZA
- 09 Jan 2025 New trial record